Dermatology Research
The Alfred dermatology research team are leaders in their fields, with decades of Australian and international experience.
Focus areas
Our researchers are focussed on new treatments for common skin conditions such as eczema and psoriasis as well as advancements in the treatment of more rare conditions such as vitiligo, hidradenitis suppurativa, bullous pemphigoid and urticaria.
Achievements
Professor Johannes Kern (Alfred Dermatology/Monash Central Clinical School) together with Dr Asolina Braun (Monash Biomedicine Discovery Institute) received a LEO Foundation grant for their project to identify antigen triggers of psoriasis.
Alfred dermatology clinical trials participate in the Medical Research Future Funds (MRFF) funded SiroSkin trial on prevention of skin squamous cell carcinoma in solid organ transplant recipients.
Professor Johannes Kern is the global coordinating investigator of the CSL324_1002 phase IB, first in-patient trial, for patients with palmoplantar pustulosis and hidradenitis suppurativa.
Our Team
Johannes is a conjoint Professor and Director of Dermatology, Monash University School of Translational Medicine and Alfred Health.
A/Prof Michelle Goh is a Fellow of the Australasian College of Dermatologists (FACD). She is a consultant dermatologist at Alfred Health and member of the Adverse Drug Reaction committee. Her areas of interest are complex skin cancers especially in patients who are immunosuppressed, cutaneous adverse reactions to drugs including immunotherapy, and biologics therapy in inflammatory skin disease.
Charlotte, our Clinic and Trials Fellow, is a strong patient advocate and has a strong emphasis on patient-centred care. She is interested in all aspects of dermatology. Charlotte is dedicated to advancing the field of dermatology through research, as evidenced by her publications in international and local peer-reviewed journals and conferences.
Are you interested in our dermatology clinical trials?
The unit is focused on new treatments for common conditions such as eczema and psoriasis as well as advancements in the treatment of more rare conditions.
Read more
_500_333.png)
